INTRODUCTION
============

Stroke has been a leading cause of disability and death worldwide \[[@r1]\]. In China, stroke also is associated with the highest disability-adjusted life-years loss of any disease, and with over 2 million new cases annually \[[@r2]\]. Since China contains a fast ageing population, it has been a challenge to prevent and control stroke as well as its complications \[[@r3]\].

Post-stroke depression (PSD), which is an important psychosocial consequence after stroke associated with higher stroke morbidity, mortality, and recurrence, affects one in third of patients \[[@r4]\]. A meta-analysis showed that PSD significantly increased risk of death in stroke patients \[[@r5]\]. Psychopathological mechanism of PSD has been complex and unclear, which may be associated with the neurobiological dysfunctions induced by ischemic stroke, such as the neuroinflammatory caused by ischemia, stress activation of the hypothalamic-pituitary-adrenal (HPA) axis, as well as the dysfunction of adaptive response \[[@r6]\].

Retinoic acid (RA), produced by the metabolism of vitamin A, makes effects on cell growth, differentiation, organogenesis, and mucosal immune responses \[[@r7], [@r8]\]. Some studies had reported that RA made regulatory effects on cardiac development and protective effects on vascular systems \[[@r9], [@r10]\]. Liu et al. \[[@r11]\] revealed that serum RA level was related to the reduced risk of death in patients with coronary artery disease. Furthermore, low circulating levels of RA were reported to link with uplifted risk of mortality in ischemic stroke \[[@r12]\].

Nucleus accumbens shell is crucial for depression and one study reported that RA signaling pathway was enhanced in this region \[[@r13]\], which influenced on the emotional behavior, such as depression and anxiety \[[@r14]\]. Accumulating studies have showed an association between RA and depression development \[[@r15]--[@r17]\]. However, the relationship between RA and PSD has not elucidated. We conducted a prospective single-center cohort study on patients with acute ischemic stroke (AIS) for evaluating the relationship between RA serum levels and PSD, and the clinical significance of RA was also compared with other known PSD indicators.

RESULTS
=======

Basic information
-----------------

363 patients with AIS were recruited. As shown in the [Figure 1](#f1){ref-type="fig"}, 305 patients were included. In the follow-up, 51 patients had passed away and 15 patents had lost follow-up or decided to quit, leaving 239 individuals ([Figure 1](#f1){ref-type="fig"}). For all the included patients, 138(57.7%) were male, with median age of 65(IQR, 56-77). At admission, the National Institutes of Health and Stroke Scale (NIHSS) score (median \[IQR\]) was 7 \[[@r4]--[@r11]\], and 31(13.0%) patients received thrombolytic therapy. The median RA serum level in patients with ischemic stroke was 2.45 ng/ml (interquartile range \[IQR\], 0.72-4.33), lower (P\<0.001) than 3.89 ng/ml of those in control cases (\[IQR\]: 2.62-5.39).

![**Study flow diagram.**](aging-12-102767-g001){#f1}

Main results
------------

For the 363 patients with AIS, 53 patients were diagnosed as depression at 3-month follow-up, showing the incidence rate was 22.2% (95%CI: 16.9%-27.4%). The characteristics of the patients with or without depression were presented ([Table 1](#t1){ref-type="table"}). Compared with those without PSD, PSD patients showed higher age, ratio of female and widowhood, stroke severity and 3-month functional disability, as well as higher serum levels of Hs-CRP and HCY.

###### Clinical characteristics in patients with and without PSD^†^.

  ------------------------------------------- ----------------- ----------------- ----------------- ---------
                                              **ALL**           **PSD**           **No-PSD**        **P**
  No                                          239               53                186               \-
  Age                                         65(56-77)         69(60-81)         63(53-73)         0.009
  Sex-male                                    138(57.7)         24(45.3)          114(61.3)         0.037
  BMI                                         24.8(22.9-26.5)   25.0(23.1-26.4)   24.7(22.8-26.5)   0.12
  Education                                   12(9-15)          12(9-15)          12(9-15)          0.85
  Hypertension                                168(70.3)         36(67.9)          132(71.0)         0.67
  Diabetes Mellitus                           63(26.4)          15(28.3)          48(25.8)          0.72
  Coronary heart disease                      52(21.8)          12(22.6)          40(21.5)          0.86
  Family history of stroke                    25(10.5)          7(13.2)           18(9.7)           0.46
  Family history of psychiatric disorders     16(6.7)           7(13.2)           9(4.8)            0.032
  Widowhood or divorced                       19(7.9)           9(17.0)           10(5.4)           0.006
  Time from stroke onset to blood collected   12.0(7.0-25.0)    13.5(8.0-28.0)    11.5(7.0-24.0)    0.029
  Stroke etiology                                                                                   0.59
   Large-artery atherosclerosis               80(33.5)          21(39.6)          59(31.7)          
   Cardio-embolism                            55(23.0)          12(22.6)          43(23.1)          
   Small vessel disease,                      47(19.7)          9(17.6)           38(20.4)          
   Other                                      24(10.0)          5(9.4)            19(10.2)          
   Unknown                                    33(13.8)          6(11.3)           27(14.5)          
  Stroke location                                                                                   0.37
   lobe                                       24(10.0)          6(11.3)           18(9.7)           
   Thalamus                                   21(8.8)           7(13.2)           14(7.5)           
   Brainstem                                  46(19.2)          10(18.9)          36(19.4)          
   Basal ganglia or lateral ventricles        116(48.5)         23(43.4)          93(50.0)          
   Cerebellum                                 6(2.5)            2(3.8)            4(2.2)            
   Multiple locations                         26(10.9)          5(9.4)            21(11.3)          
  NIHSS at admission                          7(4-11)           9(6-12)           6(3-10)           0.002
  mRS at discharge                            1(1-2)            2(1-3)            1(1-2)            0.015
  HAMD at 3-month                             4(2-7)            3(1-4)            10(7-13)          \<0.001
  Laboratory testing ^††^                                                                           
  Fasting serum glucose, mmol/l               5.75(5.11-6.25)   5.89(5.21-6.43)   5.59(4.90-6.04)   0.013
  Hs-CRP, mg/dl                               0.61(0.24-1.25)   0.68(0.28-1.48)   0.50(0.22-1.14)   \<0.001
  HCY, umol/l                                 15.5(11.9-19.7)   16.8(13.5-21.4)   14.5(10.4-18.6)   0.008
  RA, ng/ml                                   2.45(0.72-4.33)   1.27(0.46-2.75)   2.94(0.99-4.64)   \<0.001
  ------------------------------------------- ----------------- ----------------- ----------------- ---------

^**†**^Results were expressed as numbers(percentages) for categorical variables or as medians (IQR) for the continuous variables.

^††^ Serum levels of fasting serum glucose, Hs-CRP, HCY and RA in matched controls (N=100) were 5.15(4.85-5.68) mmol/l, 0.22(0.13-0.35) mg/dl, 12.5(10.8-16.7) umol/l and 3.89(2.62-5.39) ng/ml, respectively.

PSD, Post-stroke depression; NIHSS, National Institutes of Health Stroke Scale; mRS, Modified Rankin Scale; IQR, interquartile range; CRP, C-reactive protein; HCY, homocysteine; RA, Retinoic acid; BMI, body mass index; HAMD, Hamilton Rating Scale for Depression.

The serum RA levels were significantly lower in AIS patients with PSD (median \[IQR\]: 1.27\[0.46-2.75\] vs. 2.94\[0.99-4.64\]; Z=4.098, P\<0.001, [Figure 2](#f2){ref-type="fig"}). The serum RA level was negatively correlated with the severity of depression (r\[spearman\]=-0.249, P\<0.001), which was defined with HAM-D score. Furthermore, negative correlations were observed between RA serum level and the NIHSS score (r=-0.175, P=0.007), Hs-CRP serum levels (r =-0.209, P=0.001) HCY serum levels (r=-0.132, P=0.041) and age (r =-0.184, P=0.005). The RA serum level was not fluctuated with the blood collection time from stroke onset (P=0.17).

![**RA Serum levels in stroke patients with PSD and without PSD.** All data are medians and inter-quartile ranges (IQR); P values refer to Mann-Whitney U tests for differences between groups. PSD=Post-stroke depression; RA=Retinoic acid.](aging-12-102767-g002){#f2}

The ORs and 95% CIs of PSD associated with an IQR increase in RA were compared with other risk indicators including the NIHSS score ([Table 2](#t2){ref-type="table"}). Higher serum levels of RA significantly decreased the risk of PSD. The crude OR (and 95% CI) was 0.54(0.44, 0.67). The OR was adjusted for potential confounders and the adjusted OR (95% CI) was 0.66(0.52, 0.79). In addition, age, sex, widowhood, higher initial stroke severity, 3-month functional disability and serum levels of Hs-CRP and HCY were significant indicators for depression, different from others factors ([Table 2](#t2){ref-type="table"}). Furthermore, multivariate analysis was performed to obtain adjusted OR (95% CI) of PSD associated with RA quartiles (with Q1 as reference) are shown in [Table 3](#t3){ref-type="table"}. PSD distribution for the RA quartiles ranged from 36.7% (Q1) to 8.5% (Q4) (P \<0.001). RA serum levels in Q3 and Q4 were related to less risk of PSD, which was decreased by 48% (OR=0.52; 95%CI: 0.36-0.92; P=0.039) and 67% (OR=0.36; 95%CI: 0.18-0.63; P\<0.001).

###### Conditional logistic regression models were used to estimate the associations between RA, NIHSS score, other risk factors and PSD.

  ------------------------------------------------------ ------------------------- ------------------------------ ----------------- ---------
  **Parameter**                                          **Univariate Analysis**   **Multivariate Analysis^‡^**                     
  **Crude ORs (95% CIs)**                                **P**                     **Adjusted ORs (95% CIs)**     **P**             
  Age (per unit increase)                                1.07(1.04-1.09)           0.009                          1.05(1.01-1.10)   0.012
  Sex (male vs. female)                                  0.53(0.28-0.97)           0.04                           0.64(0.35-1.00)   0.05
  BMI (per unit increase)                                0.90(0.80-1.03)           0.12                                             
  Education (per unit increase)                          1.03(0.90-1.15)           0.85                                             
  Hypertension (Yes vs. no)                              0.87(0.45-1.67)           0.67                                             
  Diabetes Mellitus (Yes vs. no)                         1.14(0.57-2.25)           0.72                                             
  Coronary heart disease (Yes vs. no)                    1.07(0.52-2.22)           0.86                                             
  Family history of stroke (Yes vs. no)                  1.42(0.56-3.61)           0.46                                             
  Family history of psychiatric disorders (Yes vs. no)   2.99(1.06-8.46)           0.03                           2.16(1.01-6.15)   0.04
  Widowhood or divorced (Yes vs. no)                     3.60(1.38-9.60)           0.006                          3.04(1.25-9.03)   0.02
  Time from stroke onset to blood collected              1.17(1.05-1.31)           0.029                          1.08(0.97-1.28)   0.08
  Stroke etiology                                                                                                                   
   Large-artery atherosclerosis                          0.97(0.47-2.02)           0.94                                             
   Cardio-embolism                                       1.41(0.75-2.66)           0.42                                             
   Small vessel disease,                                 0.80(0.46-1.77)           0.58                                             
   Other                                                 0.92(0.33-2.58)           0.87                                             
   Unknown                                               0.75(0.29-1.93)           0.55                                             
  Stroke location                                                                                                                   
   lobe                                                  1.19(0.45-3.17)           0.73                                             
   Thalamus                                              1.87(0.72-4.92)           0.20                                             
   Brainstem                                             0.97(0.45-2.11)           0.94                                             
   Basal ganglia or lateral ventricles                   0.77(0.42-1.42)           0.77                                             
   Cerebellum                                            1.78(0.32-10.02)          0.51                                             
   Multiple locations                                    0.82(0.29-2.29)           0.70                                             
  NIHSS at admission (per unit increase)                 1.07(1.04-1.10)           0.002                          1.04(1.01-1.09)   0.009
  mRS at discharge (per unit increase)                   1.24(1.13-1.32)           0.015                          1.15(1.07-1.29)   0.04
  Laboratory testing                                                                                                                
  Fasting serum glucose (per unit increase)              1.15(1.03-1.27)           0.013                          1.08(1.01-1.23)   0.04
  Hs-CRP (per unit increase)                             1.38(1.16-1.63)           \<0.001                        1.25(1.09-1.51)   0.002
  HCY (per unit increase)                                1.04(1.01-1.07)           0.012                          1.02(1.00-1.06)   0.04
  RA (per IQR increase)                                  0.54(0.44-0.67)           \<0.001                        0.66(0.52-0.79)   \<0.001
  ------------------------------------------------------ ------------------------- ------------------------------ ----------------- ---------

^‡^Factors adjusted in multivariate analysis were defined in the univariate analysis, including age, sex, family history of psychiatric disorders (yes vs. no), widowhood or divorced (yes vs. no), time from stroke onset to blood collected, NIHSS at admission, mRS at discharge, serum levels of glucose, Hs-CRP, HCY and RA.

PSD, Post-stroke depression; NIHSS, National Institutes of Health Stroke Scale; mRS, Modified Rankin Scale; IQR, interquartile range; CRP, C-reactive protein; HCY, homocysteine; RA, Retinoic acid; BMI, body mass index; OR, odd ratio; CI, Confidence Interval.

###### Multivariate analysis to estimate adjusted OR (95% CI) of PSD associated with RA quartiles (with Q1 as reference).

  ------------------------- -------------------- ---------------------------- ---------------------------- ----------------- ---------
  **RA quartiles (No.)†**   **No. of PSD (%)**   **Univariate Analysis**      **Multivariate Analysis‡**                     
  **Crude ORs (95% CIs)**   **P**                **Adjusted ORs (95% CIs)**   **P**                                          
  Q1(60)                    22(36.7)             Reference                    \-                           Reference         \-
  Q2(60)                    16(26.7)             0.63(0.29-1.37)              0.24                         \-                \-
  Q3(60)                    10(16.7)             0.35(0.15-0.82)              0.013                        0.52(0.36-0.92)   0.039
  Q4(59)                    5(8.5)               0.16(0.06-0.48)              \<0.001                      0.36(0.18-0.63)   \<0.001
  ------------------------- -------------------- ---------------------------- ---------------------------- ----------------- ---------

†RA quartiles were defined as Q1: \<0.72ng/ml; Q2: (0.72-2.45) ng/ml; Q3: (2.46-4.33) ng/ml; Q4: \>4.33 ng/ml.

‡Factors adjusted in multivariate analysis were defined in the univariate analysis, including age, sex, family history of psychiatric disorders (yes vs. no), widowhood or divorced (yes vs. no), time from stroke onset to blood collected, NIHSS at admission, mRS at discharge, serum levels of glucose, Hs-CRP, HCY and RA.

PSD, Post-stroke depression; NIHSS, National Institutes of Health Stroke Scale; mRS, Modified Rankin Scale; IQR, interquartile range; CRP, C-reactive protein; HCY, homocysteine; RA, Retinoic acid; OR, odd ratio; CI, Confidence Interval.

The cut-off value of RA for predicting PSD was calculated from ROC curves. When the RA serum level was 2.8ng/ml, the AUC was 0.69 (95% CI, 0.61-0.76), providing a best sensitivity of 77.4% and specificity of 51.6% ([Figure 3](#f3){ref-type="fig"}). RA presented a better discriminatory ability than that of age (AUC, 0.58; 95%CI, 0.50-0.64; P=0.001), sex (AUC, 0.55; 95%CI, 0.47-0.61; P\<0.001) and was within the range of the NIHSS score (AUC, 0.71; 95%CI, 0.63-0.78; P=0.42). In addition, RA was superior to other serum indicators, including Hs-CRP (AUC, 0.62; 95% CI, 0.56--0.69; P=0.006), HCY (AUC, 0.63; 95% CI, 0.58--0.70; P=0.012), and glucose (AUC, 0.52; 95% CI, 0.42--0.58; P\<0.001). A multivariate model was constructed with reduced levels of RA (\<cut-off=2.8ng/ml) combining with the other factors and the results showed predictive significance (PSD: OR=3.01 \[95% CI, 2.34-4.98\]; P\<0.001\]).

![**Receiver operator characteristic curve demonstrating sensitivity as a function of 1-specificity for predicting the PSD based on the RA serum levels.** PSD= Post-stroke depression; RA=Retinoic acid.](aging-12-102767-g003){#f3}

DISCUSSION
==========

Previous studies have confirmed that PSD was caused by multiple factors, conformed to the biopsychosocial model of mental illness \[[@r18]\]. RA functioned in the development of the central nervous system \[[@r19]\]. In our prospective cohort study, the RA was proved as a new and independent predictor for indicating 3-month PSD in ischemic stroke patients. It was compatible with the existing indicator of clinical NIHSS score, while superior to that of other indicators.

Consistent with this study, Duan et al. \[[@r20]\] reported that decreased serum levels of RA at baseline were related to the risk of 3-month depression in AIS patients and Hou et al. \[[@r21]\] showed that reduced RA serum level was associated with 3-month poststroke cognitive impairment (PSCI) in AIS patients. PSD might occur through a pathophysiological pathway other than classical depression \[[@r22]\]. PSD may greatly influence the prognosis of stroke \[[@r23]\], both depression symptoms and cognitive impairment were independent predictors of impaired higher-level functioning and community reintegration 2 to 3 years after stroke \[[@r24]\]. A study showed that PSD made negative effects on functional outcome, despite of pharmacological therapy \[[@r25]\].

Various parameter would be tested on admission, some of which were probably associated with PSD, for. instance, vitamin D \[[@r26]\], vitamin B \[[@r27]\], insulin-like growth factor 1 \[[@r28]\], interleukin-6 \[[@r29]\]; hs-CRP \[[@r30]\], neopterin \[[@r31]\], tumor Necrosis Factor--α \[[@r32]\], and irisin \[[@r33]\]. Timely and accurate risk assessment was useful for depression prevention and care of stroke patients \[[@r34]\]. Our study illustrated that serum RA level was additionally helpful for predicting the 3-month PSD in AIS patients.

Significant association of RA level and age in PSD patients had been found. This is not surprising that the absorption of nutrients such as vitamin A decrease among older patients. Thus, the age would contribute to the association between RA and PSD. However, this relationship persists after adjusting for age in multivariate analysis. Furthermore, patients with depression was accompanied with higher infarct volumes and severer functional disability. RA levels were negatively correlated with the functional disability degree. The association between RA and PSD might be resulted from the stroke severity and disability. Again, correlation still persists after adjusting for these factors in multivariate analysis. Thus, the role of RA in pathophysiology of PSD might be functioned through the following pathways. First, RA played role in both the innate and adaptive immune systems \[[@r8]\], thus regulating the brain function at the cellular and systemic levels, finally functioned in pathology of depression \[[@r35]\]. Second, RA promoted the induction of proinflammatory cytokines and the maintenance of tissue homeostasis after the brain ischemia, finally contributing to the pathogenesis of mood disorders \[[@r36], [@r37]\]. In mice with chronic inflammation in the ileum, oral supplementation with RA could alleviate inflammation by regulating the balance between the Th17 and Treg populations. In addition, the number of CD103+ DCs and RALDH2 expression would be enhanced via a positive feedback mechanism \[[@r38], [@r39]\]. Third, neurovascular unit dysfunction with blood--brain barrier (BBB) hyperpermeability contributed to depressive disorder \[[@r40]\]. In an in vitro oxygen--glucose deprivation (OGD) treatment, RA made protective effects on BBB, depending on RA receptor α \[[@r41]\]. Fourth, increased oxidative stress in cerebral tissues during ischemia had been proposed to implicate in the pathogenesis of depressive-like symptoms following stroke \[[@r42]\]. One study showed that RA reduced staurosporine-induced oxidative stress and apoptosis and supported the antioxidant defense system \[[@r43]\]. One study reported that all-trans-RA (at-RA) increased nitric oxide (NO) synthesis in endothelial cells \[[@r44]\]. NO mechanism in the protective effect of naringin against PSD in mice had been recommended \[[@r45]\]. Fifth, bone morphogenetic protein (BMP) signaling in the hippocampus regulated depression, suppressed BMP signaling involved in the effects of some antidepressants \[[@r46]\]. 9c-RA had protective effects against ischemic brain injury, and these effects involve BMP \[[@r47]\]. Lastly, RA and RA receptor (RAR) and their complex play roles in innate and adaptive immunity \[[@r48]\]. In addition, RA showed neuroprotective activity, which could increase barrier tightness in human-induced pluripotent stem cell-derived brain endothelial cells by activating RARα, RARγ, and RXRα \[[@r49]\]. RAR plays both sides of homeostatic plasticity \[[@r50]\], and Chiang et al., \[[@r51]\] showed that RAR contributed to long-term depression, revealing a novel and unexpected role for vitamin A in higher cognitive functions. RARα was implicated in the activation of HPA axis thus participating in the etiology of depression \[[@r52]\].

Observative research design could not clarify the relationship between the RA, depression and outcomes in stroke patients. Machado-Pereira et al. \[[@r53]\] suggested that systemic administration of RA-loaded nanoparticles protected neurovascular integrity and improved the inflammatory environment from ischemia in the immature brain, demonstrating the effects of RA in the regulation of neuroinflammation. Plane et al. \[[@r54]\] showed that the RA could improve the survival of adult-generated subventricular zone-derived neurons and stimulate post-stroke function recovery. 9-cis-RA had neuroprotective effects against ischemia-related brain injury \[[@r55]\]. At-RA showed potent therapeutic efficacy in ischemic stroke by attenuating neural inflammation through STAT1 signaling \[[@r56]\]. In cerebral ischemia rats, the infarct volume could be reduced with RA, and the neural functional recovery would be enhanced \[[@r19]\]. The role of serum RA during stroke, and whether supplemented RA could prevent depression to improve stroke prognosis need further experimental validation.

Study strengths and limitations
-------------------------------

This study included first-ever AIS patients admitted 48 h within the onset of symptoms. These samples were more representative of the acute state. Furthermore, a range of confounding risk factors had been collected and adjusted. Lastly, we used the method of interquartile range in statistical analysis.

There were still some notable limitations. First, this is a preliminary study with a small sample size (N=239) from one single center. The conclusion could not be over-interpreted. Second, patients with a lifespan of less than three months and aphasia were excluded, and these patients might be suffered from depressive symptoms. This might cause a selection bias, resulting in a lower rate of PSD than actual data. Third, the PSD patients\' quality of life was not assessed in this study. Fourth, serum level of RA was tested once at admission, thus the changes in the disease course could not be monitored. RA levels were assessed without previous vitamin A and/or base treatment, which may affect RA determination. Thus, the results should be verified in the future. Furthermore, we tested serum rather than cerebral spinal fluid RA levels, thus RA levels in the central nervous system could not been determined. Lastly, this was an observational cohort study which could not draw any causal relationship. Whether maintaining normal RA serum level favored for PSD prevention should be further investigated.

In conclusion, reduced RA serum level was correlated to higher risk of 3-month depression in AIS patients, suggesting that RA may be a promising predictive biomarker for PSD. This may be used for improving prediction of depression and assignment of effective treatment for stroke in the future.

MATERIALS AND METHODS
=====================

Ethical statement
-----------------

This study was reviewed and approved by the Patient Research Ethics Committee of the Sichuan Provincial People\'s Hospital (Permission Numbers: 2016-03-18A) and conducted strictly adhered to the principles of the Declaration of Helsinki. Written informed consents were obtained from all participants or from their relatives (e.g., paralysis or blindness).

Included patients
-----------------

This single-center prospective cohort study was conducted in Chengdu, China. From September 1, 2017 to October 30, 2018, all patients were first-ever AIS who were admitted to the Department of Emergency of our hospital. AIS was confirmed according to the criteria of WHO Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (WHO-MONICA) \[[@r57]\]. The inclusion criteria included: (1) stroke was diagnosed based on magnetic resonance imaging (MRI) and/or computerized tomography (CT). (2) symptom onset time were within 48hours. Furthermore, the exclusion criteria was as follows: (1) severe aphasia and/or cognitive impairment, decreased level of consciousness and dementia; (2) severe neurological illness (e.g., Parkinson's disease, Alzheimer Disease); (3) other medical illness (e.g., cancer, acute infection and liver and/or renal insufficiency); (4) a history of depression or other psychiatric disorders; (5) survival period \< 3 months; (6) current use of vitamin A supplementation.

At the same time, 100 healthy volunteers with matched age and sex were recruited in control group from hospital medical examination center. Exclusion criteria for patients, was also applied to the control group. In addition, the psychiatric or cerebrovascular diseases were excluded by a neurological doctor (not the author). The Hamilton Scale in those subjects should less than 7.

Clinical variables at admission
-------------------------------

At admission, the basic information (age, sex, education and BMI), vascular risk factors (hypertension, diabetes mellitus, coronary heart disease and family history of stroke), family history of psychosis and marital status were recorded. Stroke severity was analyzed by skilled neurologists according to the NIHSS score \[ranged from 0 to 42\]; higher score indicated severer disease) \[[@r58]\]. MRI was used to evaluate the site and cause of stroke within 24hours after admission. Stroke etiology was evaluated with the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria \[[@r59]\]. In addition, functional outcome was achieved at discharge based on the modified Rankin Scale (mRS) blinded to RA serum levels \[[@r60]\].

Assessment of depression
------------------------

The depression was the primary end point of AIS patients in the 3-month follow-up. The depression was defined by the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria. Patients with a diagnosis of PSD must show depressed mood or loss of interest or pleasure, accompanied with 2\~5 symptoms of major depression lasted for at least 2 weeks \[[@r61]\]. In addition, the validated Chinese translation Hamilton Depression Rating Scale 17 items (HDRS, also abbreviated HAMD) was also used to quantify the severity of depressive symptoms \[[@r62]\]. Cut-off threshold for depression were chosen as \>7 points for each of the HDRS \[[@r63]\]. Good internal consistency of HDRS was observed in the patients included in our study (Cronbach\'s α for HDRS-was 0.82). During the follow-up, antidepressant medication will be given immediately if the patients were diagnosed as PSD. The all-cause mortality within the 3-month follow-up was the secondary end point. Outcome assessment was performed by two skilled physician who were blind to the patients' information. A structured telephone interview was performed on the patient or their relatives.

Blood sampling and biomarkers testing
-------------------------------------

Fasting venous blood of patients was collected on admission, within 72 h after the onset of symptom (within 0--3\[n=25\], 3--12 \[n=94\], 12--24 \[n=52\], and 24--72\[n=68\]). The serum was obtained by centrifuge at 3000 g and then frozen at −70 °C until testing. The RA serum level was quantified with ELISA kit (catalog no. MBS705877; MyBio-Source). Previous studies had suggested the high sensitivity and specificity of this method in the determination of human RA \[[@r12], [@r64]\]. This kit showed slight cross-reactivity with vitamin B-12(within 10%), vitamin D (within 8%) and vitamin A (within 10%). The coefficient of variance for the inter-assay and intra-assay repeatability was less than 10% and 8%, respectively. In addition, the serum levels of other parameters were also tested with standard methods, including homocysteine (HCY), hypersensitive C-reactive protein (Hs-CRP) and fasting blood glucose (FBG).

Statistical analysis
--------------------

The normal distribution of data was evaluated with Kolmogorov-Smirnov test. The categorical variables and continuous variables were expressed as numbers(percentages) or edians (interquartile range, IQR), respectively. The comparison among groups was performed with Student\'s t-test or Mann-Whitney\'s U test. Correlation was assessed with Spearman\'s correlation coefficient.

The correlation between PSD and RA serum level was evaluated with conditional logistic regression models. A range of risk factors of PSD and potential confounders were confirmed according to univariate analysis. We adjusted the confounders in the model, including age, sex, family history of psychosis (yes vs. no), widowhood or divorced (yes vs. no), NIHSS at admission, time from stroke onset to blood collection, mRS at discharge, FBS, Hs-CRP, HCY and RA. The association between RA and PSD were presented as odds ratio (OR) and 95% confidence intervals (95% CI) associated with an interquartile range (IQR) increase. Furthermore, multivariate analysis was also used to obtain adjusted OR (95% CI) of PSD associated with RA quartiles (with Q1 as reference).

Accuracy of RA serum level and other factors to predict PSD was evaluated with ROC. Optimal RA serum level in the ROC was confirmed with the level with the highest Yuden index, for predicting depression symptoms after stroke. The effects of reduced levels of RA (\<cut-off value, defined by ROC analysis) on PSD was also assessed. Statistics was performed with SPSS 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 8.0(GraphPad Software., San Diego, CA 92108, USA). P\< 0.05 was considered as statistically significant.

Ethics
------

Written informed consents were obtained from all patients; and, this study conformed to the principles of the Declaration of Helsinki were approved by the investigational review board of the Sichuan Provincial People\'s Hospital.
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